Clinical Trial Highlights – Infusion Therapies
Neha Prakash MD
Parkinson’s Disease and Movement Disorders Center, University of Connecticut Health Center, Farmington, CT, USA
Kevin McFarthing PhD
Parkinson’s advocate, Innovation Fixer Ltd, Oxford, UK To whom correspondence should be addressed at kevinDOTmcfarthingATinnovationfixerDOTcom
Tanya Simuni MD
Parkinson’s Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
[Journal of Parkinson’s Disease 10(1), 2020, 5–17, DOI 10.3233/JPD-199005]
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd199005
On page 6, line 4, it should say (76%), not (75%).
On page 6, line 5, the following text needs to be deleted:
“However, recent data from the GREENFIELD study reports only 16% device related AE [5].”
On page 6, in the References, the following reference should not have been included:
[5] L. Lopiano, N. Modugno, P. Marano, M. Sensi, G. Meco, P. Solla, G. Gusmaroli, F. Tamma, F. Mancini, R. Quatrale, R. Zangaglia, A. Bentivoglio, R. Eleopra, G. Gualberti, G. Melzi, A. Antonini, Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study, J. Neurol. 266 (2019) 2164–2176. doi:10.1007/s00415-019-09337-6.
